SEC Form 4 · accession 0001567619-18-003780
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — EVP, Chief Commercial Officer
Period of report
Oct 3, 2018
Accepted (ET)
Oct 5, 2018 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 3, 2018 | S | 1,000 | $98.9848 | D | 49,135 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on September 10, 2018.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $98.76 to $99.18. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.